Predictors of Perioperative Vasoactive Drug Requirement During Retroperitoneal Adrenalectomy for Pheochromocytoma: A Retrospective Exploratory Study

 

 Permissions and Reprints

Abstract

The aim of the present study was to test a hypothesis that baseline systemic vascular resistance index (SVRI) assessed by method of transpulmonary thermodilution predicts perioperative requirement for vasoactive drugs. The primary outcomes were: (1) peak vasoactive-inotropic score (VIS) and (2) peak dose of hypotensive drugs at any stage of surgery. The main exposure variable was baseline SVRI. Hemodynamics were retrospectively assessed by transpulmonary thermodilution in 50 adults who had undergone posterior retroperitoneal surgery for pheochromocytoma. Univariate linear regression analysis showed predictive value of SVRI on VIS [regression coefficient, 95% CI; 0.024 (0.005, 0.4), p=0.015]. Other significant factors were the history of peak diastolic pressure, baseline MAP, baseline betablocker therapy, and history of coronary artery disease (CAD). After adjustment of SVRI for the history of CAD, its prognostic value became non-significant [0.018 (0.008, 0.03), p=0.063 and 29.6 (19, 40.2), p=0.007 for SVRI and history of CAD, respectively]. Requirements of vasodilators were predicted by baseline adrenergic activity [0.37 (0.005, 0.74), p=0.047]. In conclusion, baseline SVRI is associated with perioperative requirement of vasopressor drugs, but history of CAD is a stronger prognostic factor for vasopressor support. Perioperative requirement in vasodilators is associated with baseline adrenergic activity.

Publication History

Received: 05 May 2021

Accepted after revision: 15 September 2021

Article published online:
05 November 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Bajwa S, Bajwa S. Implications and considerations during pheochromocytoma resection: A challenge to the anesthesiologist. Indian J Endocrinol Metab 2011; 15: 337
  CrossrefPubMedGoogle Scholar
• 2 Livingstone M, Duttchen K, Thompson J. et al Hemodynamic stability during pheochromocytoma resection: Lessons learned over the last two decades. Ann Surg Oncol 2015; 22: 4175-4180
  CrossrefPubMedGoogle Scholar
• 3 Naranjo J, Dodd S, Martin YN. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2017; 31: 1427-1439
  CrossrefPubMedGoogle Scholar
• 4 Groeben H, Walz MK, Nottebaum BJ. et al International multicentre review of perioperative management and outcome for catecholamine-producing tumours. Br J Surg 2020; 107: e170-e178
  CrossrefPubMedGoogle Scholar
• 5 Grocott HP. Safety assessments in the avoidance of preoperative α-receptor blockade in phaeochromocytoma surgery: the pitfalls of a zero numerator. Br J Anaesth 2017; 119: 545-546
  CrossrefPubMedGoogle Scholar
• 6 Schimmack S, Kaiser J, Probst P. et al Meta-analysis of α-blockade versus no blockade before adrenalectomy for phaeochromocytoma. Br J Surg 2020; 107: e102-e108
  CrossrefPubMedGoogle Scholar
• 7 Weingarten TN, Welch TL, Moore TL. et al Preoperative levels of catecholamines and metanephrines and intraoperative hemodynamics of patients undergoing pheochromocytoma and paraganglioma resection. Urology 2017; 100: 131-138
  CrossrefPubMedGoogle Scholar
• 8 Gaujoux S, Bonnet S, Lentschener C. et al Preoperative risk factors of hemodynamic instability during laparoscopic adrenalectomy for pheochromocytoma. Surg Endosc 2016; 30: 2984-2993
  CrossrefPubMedGoogle Scholar
• 9 Wolf KI, Santos JRU, Pacak K. Why take the risk? We only live once: the dangers associated with neglecting a pre-operative alpha adrenoceptor blockade in pheochromocytoma patients. Endocr Pract 2019; 25: 106-108
  CrossrefPubMedGoogle Scholar
• 10 Gaies MG, Gurney JG, Yen AH. et al Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. 2010; 11: 234-238
  PubMedGoogle Scholar
• 11 Koponen T, Karttunen J, Musialowicz T. et al Vasoactive-inotropic score and the prediction of morbidity and mortality after cardiac surgery. Br J Anaesth 2019; 122: 428-436
  CrossrefPubMedGoogle Scholar
• 12 Walz MK, Peitgen K, Walz MV. et al Posterior retroperitoneoscopic adrenalectomy: Lessons learned within five years. World J Surg 2001; 728-734
  CrossrefPubMedGoogle Scholar
• 13 Grocott HP. Perioperative considerations in the management of pheochromocytoma: The details behind the changing dogma. J Cardiothorac Vasc Anesth 2018; 32: e11-e12
  CrossrefPubMedGoogle Scholar
• 14 Rao N, Ramachandran R, Tandon N. et al Surgical and hemodynamic outcomes in pheochromocytoma surgery: a prospective cohort study. Urology 2016; 98: 103-106
  CrossrefPubMedGoogle Scholar
• 15 Hemodynamic monitoring lessons from the ICU. Michael R. Pinsky, Jean-Louis Teboul J-L, Vincent J-L. Eds Berlin: Springer; 2019
• 16 Perioperative hemodynamic monitoring and goal directed therapy: From theory to practice Cannesson M, Pearse R. Eds Cambridge: Cambridge University Press; 2014
• 17 Groeben H, Nottebaum BJ, Alesina PF. et al Perioperative α-receptor blockade in phaeochromocytoma surgery: An observational case series. Br J Anaesth 2017; 118: 182-189
  CrossrefPubMedGoogle Scholar
• 18 Tufton N, Gunganah K, Hussain S. et al Alpha blockade – not to be underdone. Clin Endocrinol (Oxf) 2017; 86: 306-308
  CrossrefPubMedGoogle Scholar
• 19 Challis BG, Casey RT, Simpson HL. et al Is there an optimal preoperative management strategy for phaeochromocytoma/paraganglioma?. Clin Endocrinol (Oxf) 2017; 86: 163-167
  CrossrefPubMedGoogle Scholar

• Supplementary Material